Home > Oncology > ASCO 2019 > Paediatric Oncology > Entrectinib produces rapid and durable responses in children with refractory CNS and solid tumours

Entrectinib produces rapid and durable responses in children with refractory CNS and solid tumours

Presented By
Dr Giles W. Robinson, St. Jude Children’s Research Hospital, USA
Conference
ASCO 2019
Medical writer: Jasenka Piljac Žegarac, PhD Entrectinib, an oral inhibitor of TRKA/B/C, ROS1, and ALK tyrosine kinases and a central nervous system (CNS)–penetrant, was well tolerated and produced rapid and durable responses in patients with refractory CNS and solid tumours harboring NTRK1/2/3, ROS1, and ALK fusions, as well as in a patient with ALK-mutated neuroblastoma (Abstract 10009). “Entrectinib is extremely promising in its anti-tumour activity and progression-free survival, and, because there were no responses in nontarget patients, this study now remains open but only for patients with target gene fusions,” Giles W. Robinson, MD, of St. Jude Children’s Research Hospital, said during an Oral Abstract Session on June 2. Entrectinib has shown efficacy in several prior phase I (STARTRK-1 and ALKA-372-001) and phase II (STARTRK-2) trials of patients with NTRK fusion–positive solid tumours. In May 2017, it was g...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on